表决结果：同意 2 票，反对 0 票，弃权 0 票。 二、会议审议情况 全体独立董事经过审议，审议通过了如下议案： 一、《关于控股子公司增资扩股引进投资者暨关联交易的议案》 经审核，我们认为：本次公司参与控股子公司烟台蓝纳成生物技术股份有限 公司融资事项，符合公司未来战略发展的需求，不会对公司生产经营活动和财务 产生不利影响；本次增资交易价格根据其 C 轮融资的《增资协议》确定，不存 在损害公司及公司股东利益的情形。 烟台东诚药业集团股份有限公司 第六届董事会第四次独立董事专门会议 一、独立董事专门会议召开情况 2025 年 7 月 18 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 召开了第六届董事会第四次独立董事专门会议。会议通知于 2025 年 7 月 14 日以 通讯方式送达，会议应出席独立董事 2 人，实际出席独立董事 2 人，会议的召集、 召开和表决程序符合《公司章程》、《上市公司独立董事管理办法》、《独立董事工 作制度》等规定。 独立董事：李方、赵大勇 2025 年 7 月 18 日 ...

关于控股子公司增资扩股引进投资者暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002675 证券简称：东诚药业 公告编号：2025-033 烟台东诚药业集团股份有限公司 特别提示： 1、本次关联交易：烟台东诚药业集团股份有限公司以3,000万元人民币参与控 股子公司烟台蓝纳成生物技术股份有限公司后续融资，认购其新增注册资本90.6235 万元人民币。 2、本次交易构成关联交易，不构成重大资产重组。 3、本次交易实施不存在重大法律障碍。 4、本次交易已经提交公司第六届董事会第十一次会议审议通过，无需提交股东 大会审议，关联董事由守谊先生回避了表决，其余4名非关联董事一致通过了该议案。 一、交易概述 烟台东诚药业集团股份有限公司（以下简称"东诚药业"或"公司"）曾于2025年2 月14日第六届董事会第八次会议审议通过了《关于控股子公司增资扩股引进投资者 暨关联交易的议案》，同意公司控股子公司烟台蓝纳成生物技术股份有限公司（以 下简称"蓝纳成"或"目标公司"）以增资扩股方式引入温州瑞力医疗新消费产业投资 合伙企业（有限合伙）、上海遴珏企 ...

证券代码：002675 证券简称：东诚药业 公告编号：2025-034 第六届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025年7月18日，烟台东诚药业集团股份有限公司（以下简称"公司"）第六届 监事会第九次会议在本公司会议室召开。会议通知于2025年7月14日以通讯方式发送 至全体监事。本次会议由监事会主席柳青林先生主持，应出席监事3人，实出席监事 3人，董事会秘书刘晓杰先生列席，符合法律法规及公司章程的有关规定。 二、监事会会议审议情况 全体监事一致通过决议如下： （一）审议通过了《关于控股子公司增资扩股引进投资者暨关联交易的议案》 经审核，监事会成员一致认为，本次交易是基于公司未来发展战略，满足目标 公司经营发展资金需求，不会影响公司的正常经营。本次增资交易价格由目标公司 C轮融资的《增资协议》确定，不存在损害公司及公司股东，尤其是中小股东利益 的情形。 内容详见公司刊载于《证券时报》、《证券日报》、《中国证券报》、《上海 证券报》和巨潮资讯网（www.cninfo.com.cn）《关于控股子公司 ...

第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002675 证券简称：东诚药业 公告编号：2025-032 烟台东诚药业集团股份有限公司 1 本议案关联董事由守谊回避表决，由公司其他 4 名非关联董事审议表决。 表决情况：同意4票，反对0票，弃权0票。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议 特此公告！ 烟台东诚药业集团股份有限公司董事会 2025年7月19日 一、董事会会议召开情况 2025年7月18日，烟台东诚药业集团股份有限公司（以下简称"公司"）在 山东省烟台经济技术开发区长白山路7号公司会议室召开了第六届董事会第十一 次会议。会议通知于2025年7月14日以通讯方式送达。会议采用现场结合通讯方 式召开，会议应到董事5人，实到董事5人。公司全体监事和高级管理人员列席 了本次会议。会议由公司董事长由守谊先生主持，会议召开符合《中华人民共 和国公司法》（以下简称"《公司法》"）及《烟台东诚药业集团股份有限公 司章程》（以下简称"《公司章程》"）等有关规定。 二、董事会会议审议情况 全体董事经过 ...

证券代码：002675 证券简称：东诚药业 公告编号：2025-031 药品批注文号：国药准字[H20103293] 结论：经材料审查，符合药品GMP要求，同意江西宜春核药生产中心投入生 产运营。 烟台东诚药业集团股份有限公司 关于江西宜春核药生产中心投入运营的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）收到全资子公 司南京江原安迪科正电子研究发展有限公司（以下简称"安迪科"）的通知，通 知其全资子公司江西安迪科药业有限公司（以下简称"江西安迪科"）收到江西 省药品监督管理局下发的《药品GMP符合性检查结果告知书》(赣药品GMP（2025） 第A0058号)，新增江西宜春核药生产中心。相关信息如下： 企业名称：江西安迪科药业有限公司 地址：江西省宜春市奉新县高新园区园区五路79号 药品名称：氟[ 18F]脱氧葡糖注射液 此次审查的通过标志着安迪科的江西宜春核药生产中心已达到投产要求，安 迪科将新增一个核药生产中心。核药生产中心投产后，将有利于安迪科开拓市场、 提升销售收入，进一步完善全国核药网络化 ...

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][54]. Core Viewpoints - The report highlights that the AD (Alzheimer's Disease) treatment sector is expected to see significant advancements, with a recommendation to focus on companies like Tonghua Jinma and Dongcheng Pharmaceutical [3][9]. - The report emphasizes the importance of innovation, international expansion, and the aging population as key themes driving the industry forward [22][43]. - The pharmaceutical index has shown a positive performance, with a 1.40% increase from June 9 to June 13, outperforming the CSI 300 index by 1.66% [5][22]. Summary by Sections 1. AD Treatment Developments - The report notes that Alzheimer's Disease (AD) is a major global health challenge, with 51.62 million cases worldwide in 2019, including 13.14 million in China [9][10]. - The innovative oral drug, Succinyl-8-hydroxy-aminoguanidine, developed by Tonghua Jinma, has shown promising results in clinical trials and is expected to be a significant player in the AD treatment market [5][21]. 2. Industry Perspectives - The report indicates that the pharmaceutical sector is transitioning from traditional growth drivers to innovative solutions, with a focus on domestic innovation and international market expansion [22][43]. - The aging population is driving demand for chronic disease treatments, and the report suggests that the healthcare payment system is evolving to support this growth [41][43]. 3. Market Performance - The report provides a detailed analysis of stock performance, noting that 218 stocks increased in value while 263 decreased during the reporting period [5][22]. - Specific stocks such as Yiming Pharmaceutical and Sai Sheng Pharmaceutical have shown significant gains, while others like Renmin Tongtai have experienced notable declines [25][26]. 4. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and those with strong international expansion capabilities, such as Heng Rui Pharmaceutical and Keren Pharmaceutical [43][44]. - It also highlights the importance of investing in sectors related to aging and outpatient consumption, suggesting companies like Kunming Pharmaceutical and Yuyue Medical [44].

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced that its subsidiary, Lannacheng, has completed the enrollment of all 488 participants in the Phase III clinical trial for the radiopharmaceutical Fluorine-18 [18F] PSMA peptide injection, which is intended for PET imaging in prostate cancer patients. This product currently has no domestic competitors, while similar products are available internationally [1]. Group 1 - The Phase III clinical trial for Fluorine-18 [18F] PSMA peptide injection has successfully enrolled 488 subjects [1]. - The drug targets PSMA and is designed for PET imaging in prostate cancer patients [1]. - There are currently no similar products available in the domestic market, while international competitors exist [1]. Group 2 - Lantheus's 2024 annual report indicates that its product, 18F-PSMA diagnostic PYLARIFY, is projected to achieve sales revenue of $1.1 billion in 2024 [1]. - The total research and development investment for the Fluorine-18 [18F] PSMA peptide injection project has reached approximately 119 million yuan [1].

烟台东诚药业集团股份有限公司 证券代码：002675 证券简称：东诚药业 公告编号：2025-030 二、药物的其他情况 关于氟[ 18F]思睿肽注射液 III 期临床试验完成全部受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"或"上市公司"）控 股子公司烟台蓝纳成生物技术股份有限公司（以下简称"蓝纳成"）组织开展的氟[ 18F] 思睿肽注射液 III 期临床试验，目前已完成全部 488 例受试者入组。现将相关情况公 告如下： | 药物名称 | 18F]思睿肽注射液 氟[ | | | --- | --- | --- | | 剂型 | 注射剂 | | | 注册分类 | 化药Ⅰ类新药 | | | 适应症 | 适应症一 | 适应症二 | | 伦理审查意见号 | 2023BJYYEC-367-02 | 2023BJYYEC-368-02 | | 具体适应症内容 | 评 价 氟 18F] 思 睿 肽 注 射 液 [ | 评 价 氟 18F] 思 睿 肽 注 射 液 [ | | | PET/CT 显像在 ...